SX
SXTP.US 60 Degrees Pharmaceuticals, Inc. Common Stock
- Market cap
- USD 1.88M
- P/E
- -
- P/B
- -
- ROE
- -1,094.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SXTP.US undervalued?
Graham numberThe Graham number of 60 Degrees Pharmaceuticals, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
60 Degrees Pharmaceuticals, Inc. Common Stock fundamental analysis
No fundamental analysis for 60 Degrees Pharmaceuticals, Inc. Common Stock yet.
60 Degrees Pharmaceuticals, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About 60 Degrees Pharmaceuticals, Inc. Common Stock
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and …
Full company profile60 Degrees Pharmaceuticals, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
60 Degrees Pharmaceuticals, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 2.18M | 1.16M | 223K | 254K | 608K | 1.01M | 804K |
| Gross Profit | 1.48M | 310K | -209K | -221K | 223K | 224K | 47.5K |
| Operating Income | -418K | -1.12M | -1.75M | -5.15M | -9.71M | -7.76M | -9.19M |
| EBITDA | -341K | -1.01M | -2.11M | -1.43M | -7.88M | -7.28M | -9.11M |
| Net Income | -3.03M | -4.25M | -6.18M | -3.77M | -7.95M | -7.37M | -9.22M |
| EPS | -125 | -176 | -255 | -156 | -70 | -11 | -2.59 |
| Balance Sheet | |||||||
| Total Assets | 2.61M | 1.39M | 1.30M | 7.78M | 5.76M | 5.37M | 3.09M |
| Total Liabilities | 20.7M | 19.5M | 25.4M | 2.99M | 1.80M | 1.99M | 147K |
| Shareholders' Equity | -17.5M | -17.6M | -23.6M | 4.87M | 4.04M | 3.46M | 842K |
| Cash & Short-term Investments | 192K | 115K | 265K | 2.14M | 3.39M | 2.75M | 306K |
| Total Debt | 15.9M | 18.8M | 22.4M | 173K | 156K | 153K | - |
| Cash Flow | |||||||
| Operating Cash Flow | -167K | -649K | -1.01M | -4.54M | -5.65M | -6.85M | -8.56M |
| Capital Expenditure | 71.0K | 35.4K | 60.1K | 116K | 181K | 218K | 80.0K |
| Free Cash Flow | -238K | -684K | -1.07M | -4.66M | -5.83M | -7.07M | -8.60M |
| Ratios | |||||||
| ROE | - | - | - | -77.3% | -196.9% | -212.8% | -1,094.5% |
| ROA | -116.4% | -305.1% | -476.5% | -48.4% | -138.0% | -137.3% | -297.9% |
| Net Profit Margin | -139.1% | -366.4% | -2,769.5% | -1,485.1% | -1,308.0% | -732.8% | -1,145.9% |
| Debt to Equity | - | - | - | 0.04x | 0.04x | 0.04x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
60 Degrees Pharmaceuticals, Inc. Common Stock dividends
60 Degrees Pharmaceuticals, Inc. Common Stock has not paid dividends in the last 6 fiscal years.
Last stock split: 1:4 on Jan 20, 2026.
Who owns 60 Degrees Pharmaceuticals, Inc. Common Stock
- Insiders 19.39%
- Institutions 19.16%
- Public & others 61.45%
- Shares outstanding 3.52M
- Free float 2.45M
Top funds holding SXTP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 14.4K | 0.41% | 0.00% | Sep 2026 |
Top institutions holding SXTP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Kathmere Capital Management, LLC | 265K | 7.54% | +83.23% | Jun 2026 |
| Citadel Advisors Llc | 22.4K | 0.64% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 17.6K | 0.50% | 0.00% | Jun 2026 |
| Kovack Advisors Inc | 15.0K | 0.43% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 14.6K | 0.41% | -10.70% | Jun 2026 |
| UBS Group AG | 13.6K | 0.39% | -56.73% | Jun 2026 |
| Barclays PLC | 1.05K | 0.03% | -43.32% | Jun 2026 |
| Advisor Group Holdings, Inc. | 25.00 | 0.00% | 0.00% | Jun 2026 |
| Goss Wealth Management LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| TWIN PEAKS WEALTH ADVISORS LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Citigroup Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
60 Degrees Pharmaceuticals, Inc. Common Stock company profile
- Company name
- 60 Degrees Pharmaceuticals, Inc. Common Stock
- Ticker
- SXTP.US
- Exchange
- USA Stocks
- Listed since
- Jul 12, 2023
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 3
- Fiscal year end
- December
- Address
- 1025 Connecticut Avenue NW, Washington, DC, United States, 20036
- Phone
- 202 327 5422
- Website
- 60degreespharma.com
About 60 Degrees Pharmaceuticals, Inc. Common Stock
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Washington, District Of Columbia.
60 Degrees Pharmaceuticals, Inc. Common Stock management
4- Dr. Geoffrey Stuart Dow Ph.D.Chairman, CEO & President · born 1974
- Mr. Tyrone MillerChief Financial Officer · born 1975
- Ms. Kristen LandonChief Commercial Officer · born 1967
- Dr. Bryan SmithChief Medical Officer · born 1966